NEW YORK, Sept. 13, 2018 /PRNewswire/ -- Ideanomics (Seven
Stars Cloud Group, Inc.) (NASDAQ: SSC) ("Ideanomics" or the "Company"), a leading global fintech and asset digitization services
company focused on digital asset production and distribution, is pleased to announce a transaction with Liberty Biopharma (TSXV: LTY.V) (http://www.libertybiopharma.com/) in order to deliver asset digitization
for green, clean tech, medical and healthcare industries. Liberty owns CTC Life Sciences, which includes HooXi, acquired
officially by Liberty on Aug 31, 2018. Liberty intends to change its name to HooXi.
HooXi's plans for asset digitization include but are not limited to asset backed securitization and tokenization, digital
asset offerings and AI enhanced ratings. The focus of asset digitization and securitization is for cash flowing assets such as
new energy-based power generation facilities, environmental protective waste treatment centers, medical equipment leasing
financing as well as medical intellectual property.
As part of this combined asset digitization strategy and HooXi's vision as the "green tech,
clean tech, and medical health care flagship", the transaction involves a share for share swap between SSC and Liberty, for
Common shares at market value and Performance shares at market value, based on revenue and EBITDA earn-outs.
Bruno Wu, Chairman and Co-CEO of Ideanomics, "Our agreement creates an unprecedented
opportunity for Ideanomics to enter into the strategic industries of life sciences, and clean tech / green tech. These industries
are critical to the environmental sustainability and are reflective of the types of high-grade asset classes that deserve to be
brought into the rapidly forming new digital economy. We are proud to do so alongside the leadership of HooXi. We believe
that HooXi is a strong company with great growth potential, and that our proposed transaction will be complimentary to our
Ideanomics strategy in asset digitization, and beneficial to our shareholders."
"HooXi is a strong company with the ability to rapidly grow. Medical and green technologies are industries that our
shareholders are passionate about and that we seek to further service by bringing investment grade digital assets to market,"
said Norman Tsui, CEO of Liberty BioPharma Inc.
About Ideanomics
Ideanomics (Seven Stars Cloud Group, Inc.), (NASDAQ: SSC) (http://www.ideanomics.com/)
Ideanomics is determined to become one of the most prominent global digital asset providers. Relying on its core base of
fintech and digital asset production and services-based ecosystem enablement, Ideanomics is committed to delivering the best
digital assets via the best underlying technology. This approach will drive capital formation and sales across our digital asset
ecosystems.
Ideanomics customizes its technology platform for various business use cases, operates the Platform-as-a-Service (PaaS), and
partners with businesses that deliver core digital asset products.
We are focused on delivering a global multi-layer technology infrastructure ecosystem that issues, trades, and settles digital
asset transactions. We will leverage direct sales channels and automated sales systems via digital asset exchange platforms which
is inclusive of decentralized exchanges to realize digital asset distribution, social media, traditional regulated broker dealer
network as well as institutions as direct clients.
About Liberty Biopharma Inc.
Liberty Biopharma is a medical digital technology and biopharmaceutical company active in global strategic partnerships and
in-licensing of technologies and assets for rapid growth and high value solutions.
Safe Harbor Statement
This press release contains certain statements that may include "forward looking statements". All statements other
than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often
identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and
unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements
are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You
should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The
Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a
variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange
Commission and available on its website (http://www.sec.gov). All forward-looking
statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these
factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking
statements.
Media Contacts
Ideanomics
Email: pr@sevenstarscloud.io
IR Contacts
Federico Tovar, CFO Ideanomics
Chad Arroyo, CMO and CPO Ideanomics
Email: ir@sevenstarscloud.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/ideanomics-nasdaq-ssc-announces-transaction-with-liberty-biopharma-inc-tsxv-ltyv---as-part-of-their-combined-strategy-to-deliver-life-sciences-and-green-tech-asset-digitization-via-hooxi-300712255.html
SOURCE Ideanomics (Seven Stars Cloud Group, Inc.)